News

News Subscription

Feb 11. 2021
Basilea achieves preclinical milestone in oncology collaboration on potential first-in-class kinase inhibitor
Read more
Download
Feb 10. 2021
Basilea reports positive topline results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene fusion-positive patients with bile duct cancer (iCCA)
Read more
Download
Feb 09. 2021
Continued strong Cresemba® (isavuconazole) sales trigger milestone from Pfizer to Basilea of USD 10 million
Read more
Download
Jan 11. 2021
Basilea reports preliminary 2020 revenue and portfolio progress
Read more
Download
Jan 07. 2021
Basilea’s partner Asahi Kasei Pharma completes patient enrolment in phase 3 study with antifungal isavuconazole (Cresemba®) in Japan
Read more
Download
Nov 25. 2020
Basilea reports acceptance for regulatory review of Pfizer’s marketing authorization application for antifungal isavuconazole (Cresemba®) in invasive aspergillosis in China
Read more
Download
Nov 06. 2020
Basilea announces approval of antibiotic Zevtera® in China to treat community-acquired pneumonia and hospital-acquired pneumonia
Read more
Download
Oct 28. 2020
Basilea announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ramucirumab in the ongoing FIDES-03 study with derazantinib in gastric cancer
Read more
Download
Oct 26. 2020
Basilea presents preclinical data on anti-angiogenic activity of derazantinib at ENA 2020
Read more
Download
Oct 13. 2020
Basilea reports interim results from phase 1/2 study FIDES-02 exploring derazantinib in patients with advanced urothelial cancer
Read more
Download